Spriaso LLC is a biopharmaceutical company that emphasizes the development of innovative therapeutics aimed at enhancing patient compliance, particularly in the treatment of central nervous system (CNS) and gastrointestinal (GI) disorders. The company has a diverse portfolio of product candidates that have successfully completed proof of principle clinical studies, positioning them for potential New Drug Application (NDA) filings in the near future. These products are not only designed to be patient-friendly but are also backed by a robust intellectual property strategy, with multiple issued and pending patents protecting their innovations.

In addition to their product candidates, Spriaso is focused on creating unique delivery platforms that facilitate better patient adherence to treatment regimens. This commitment to improving therapeutic options reflects the company's dedication to addressing unmet medical needs in the biopharmaceutical landscape. Spriaso is actively seeking marketing partners for out-licensing opportunities, indicating a strategic approach to expanding the reach of their innovative products and technologies in the healthcare market.

United States

Spriaso is a biopharmaceutical company dedicated to improving therapeutics through innovative patient friendly product options. Spriaso has several candidates in development with a focus on the central nervous system (CNS) and gastrointestinal (GI) disorders. Our portfolio of unique products have successfully completed proof of principle clinical studies. In addition, Spriaso develops ANDA products and has received an FDA approved NDA. These products are available for out-license to a marketing partner and are protected by multiple issued and pending patents.

Spriaso LLC

Company Details